+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cancer Vaccines Market by Technology, Type, Indication and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027

  • ID: 5141685
  • Report
  • July 2020
  • Region: Global
  • 284 pages
  • Allied Analytics LLP
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
The global cancer vaccines market was valued at $4,188 million in 2019, and is projected to reach $7,303 million by 2027, registering a CAGR of 12.6% from 2020 to 2027.

Vaccine is a biological preparation that strengthens the immune system and provides acquired immunity against a specific pathogen. Cancer vaccines are popularly used to treat various types of cancers such as breast cancer, lung cancer, prostate cancer, and cervical cancer. In addition, it offers numerous benefits as it can stop the growth of tumor cells, prevents cancer relapse, and destroys tumor cells that are left behind after treatment. There are two types of vaccines available in market, namely, preventive cancer vaccines and therapeutic cancer vaccines. Preventive cancer vaccines are traditional cancer vaccines used in healthy people to prevent cancer. Therapeutic cancer vaccines are type of immunotherapy vaccines used for metastatic prostate cancer, human papillomavirus (HPV), and hepatitis B virus.

The factors that drive the cancer vaccines market are rise in prevalence of cancer such as breast cancer, prostate cancer, and cervical, lung cancer globally, and surge in investments and governmental funding for the development of cancer vaccines by manufacturers. In addition, increase in cancer vaccines usage combined with other therapies, surge in demand for cancer vaccines, the rise in public awareness toward benefits of cancer vaccines, increase in prevalence of human papilloma virus (HPV) infections, and launch of new cancer vaccines further fuel market growth. However, high cost for developing cancer vaccines and longer time span required for manufacturing a single vaccine are anticipated to restrict market growth. Furthermore, growth in transition from prophylactic to therapeutic cancer vaccines is expected to offer lucrative opportunities in the near future.

The global cancer vaccines market is segmented on the basis of technology, type, indication, end user, and region. By technology, the market is categorized into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines. By type, it is bifurcated into preventive cancer vaccines and therapeutic cancer vaccines. By indication, it is classified into cervical cancer, prostate cancer, and others. By end user, it is divided into pediatric and adult. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of four regions are provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS

By Technology
  • Dendritic Cells (DC) Cancer Vaccines
  • Recombinant Cancer Vaccines
  • Antigen/Adjuvant Cancer Vaccines
  • Viral Vector & DNA Cancer Vaccines
By Indication
  • Cervical Cancer
  • Prostate Cancer
  • Others
By Type
  • Preventive Cancer Vaccines
  • Therapeutic Cancer Vaccines
By End User
  • Pediatrics
  • Adults
By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific- LAMEA
  • Brazil
  • Argentina
  • Turkey
  • South Africa
  • Rest of LAMEA
List of key players profiled in the report
  • Advaxis Inc.
  • Amgen Inc.
  • Dynavax Technologies Corporation
  • Generex Biotechnology Corporation
  • GlaxoSmithKline plc (GSK)
  • Immunocellular Therapeutics, Ltd
  • Merck & Co., Inc.
  • Sanpower Group Co. Ltd. (Dendereon Corporation)
  • UbiVac
  • Vaccinogen, Inc.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • Oxford BioMedica.
  • Juvaris Biotherapeutics
  • Prima BioMed
Note: Product cover images may vary from those shown
2 of 3
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled in the Report
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models

Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.2. CXO Perspective

Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets.
3.2.2. Top Winning Strategies
3.3. Porter’s Five Force Analysis
3.4. Regulatory Framework
3.4.1. Fda
3.4.2. Ce Mark
3.4.3. Therapeutic Goods Administration (Tga)
3.4.4. Ministry of Health, Labour and Welfare (Mhlw)
3.5. Market Share Analysis, 2019
3.6. Market Dynamics
3.6.1. Drivers
3.6.1.1. Rise in Prevalence of Human Papilloma Virus (Hpv) Cancer
3.6.1.2. Increase in Administration of Prophylactic Cancer Vaccines
3.6.1.3. Rise in Development of New Cancer Vaccines
3.6.1.4. Launch and Approval of New Cancer Vaccines in the Market
3.6.2. Restraints
3.6.2.1. High Cost and Longer Timelines Required for Development of Cancer Vaccines
3.6.3. Opportunities
3.6.3.1. High Growth Prospects in Emerging Markets
3.6.4. Impact Analysis

Chapter 4: Cancer Vaccines Market, by Technology
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Dendritic Cells (Dc) Cancer Vaccines
4.2.1. Key Market Trends, Growth Factors, and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Analysis by Country
4.3. Recombinant Cancer Vaccines
4.3.1. Key Market Trends, Growth Factors, and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Analysis by Country
4.4. Antigen/Adjuvent Cancer Vaccines
4.4.1. Key Market Trends, Growth Factors, and Opportunities
4.4.2. Market Size and Forecast, by Region
4.4.3. Market Analysis by Country
4.5. Viral Vector and Dna Cancer Vaccines
4.5.1. Key Market Trends, Growth Factors, and Opportunities
4.5.2. Market Size and Forecast, by Region
4.5.3. Market Analysis by Country

Chapter 5: Cancer Vaccines Market, by Types
5.1. Overview
5.2. Market Size and Forecast
5.3. Preventive Cancer Vaccines
5.3.1. Market Size and Forecast, by Region
5.3.2. Market Analysis, by Country
5.4. Therapeutic Cancer Vaccines
5.4.1. Market Size and Forecast, by Region
5.4.2. Market Analysis, by Country

Chapter 6: Cancer Vaccines Market, by Indication
6.1. Overview
6.2. Market Size and Forecast
6.3. Cervical Cancer
6.3.1. Market Size and Forecast, by Region
6.3.2. Market Analysis, by Country
6.4. Prostate Cancer
6.4.1. Market Size and Forecast, by Region
6.4.2. Market Analysis, by Country
6.5. Other Indications
6.5.1. Market Size and Forecast, by Region
6.5.2. Market Analysis, by Country

Chapter 7: Cancer Vaccines Market, by End-user
7.1. Overview
7.2. Market Size and Forecast
7.3. Pediatrics
7.3.1. Market Size and Forecast, by Region
7.3.2. Market Analysis, by Country
7.4. Adults
7.4.1. Market Size and Forecast, by Region
7.4.2. Market Analysis, by Country

Chapter 8: Cancer Vaccines Market, by Region
8.1. Overview
8.1.1. Market Size and Forecast
8.2. North America
8.2.1. Key Market Trends, Growth Factors, and Opportunities
8.2.2. North America Cancer Vaccines Market, by Country
8.2.2.1. U.S.
8.2.2.1.1. U.S. Cancer Vaccines Market, by Technology
8.2.2.1.2. U.S. Cancer Vaccines Market, by Type
8.2.2.1.3. U.S. Cancer Vaccines Market, by Indication
8.2.2.1.4. U.S. Cancer Vaccines Market, by End-user
8.2.2.3. Canada
8.2.2.3.1. Canada Cancer Vaccines Market, by Technology
8.2.2.3.2. Canada Cancer Vaccines Market, by Type
8.2.2.3.3. Canada Cancer Vaccines Market, by Indication
8.2.2.3.4. Canada Cancer Vaccines Market, by End-user
8.2.2.5. Mexico
8.2.2.5.1. Mexico Cancer Vaccines Market, by Technology
8.2.2.5.2. Mexico Cancer Vaccines Market, by Type
8.2.2.5.3. Mexico Cancer Vaccines Market, by Indication
8.2.2.5.4. Mexico Cancer Vaccines Market, by End-user
8.2.3. North America Cancer Vaccines Market, by Technology
8.2.4. North America Cancer Vaccines Market, by Type
8.2.5. North America Cancer Vaccines Market, by Indication
8.2.6. North America Cancer Vaccines Market, by End-user
8.3. Europe
8.3.1. Key Market Trends, Growth Factors, and Opportunities
8.3.2. Europe Cancer Vaccines Market, by Country
8.3.2.1. Germany
8.3.2.1.1. Germany Cancer Vaccines Market, by Technology
8.3.2.1.2. Germany Cancer Vaccines Market, by Type
8.3.2.1.3. Germany Cancer Vaccines Market, by Indication
8.3.2.1.4. Germany Cancer Vaccines Market, by End-user
8.3.2.2. France
8.3.2.2.1. France Cancer Vaccines Market, by Technology
8.3.2.2.2. France Cancer Vaccines Market, by Type
8.3.2.2.3. France Cancer Vaccines Market, by Indication
8.3.2.2.4. France Cancer Vaccines Market, by End-user
8.3.2.3. UK
8.3.2.3.1. UK Cancer Vaccines Market, by Technology
8.3.2.3.2. UK Cancer Vaccines Market, by Type
8.3.2.3.3. UK Cancer Vaccines Market, by Indication
8.3.2.3.4. UK Cancer Vaccines Market, by End-user
8.3.2.4. Italy
8.3.2.4.1. Italy Cancer Vaccines Market, by Technology
8.3.2.4.2. Italy Cancer Vaccines Market, by Type
8.3.2.4.3. Italy Cancer Vaccines Market, by Indication
8.3.2.4.4. Italy Cancer Vaccines Market, by End-user
8.3.2.5. Spain
The Spain Cancer Vaccines Market Was Valued at $107.67 Million in 2019, and is Projected to Reach $158.00 Million by 2027, Registering a CAGR of 9.5%.
8.3.2.5.1. Spain Cancer Vaccines Market, by Technology
8.3.2.5.2. Spain Cancer Vaccines Market, by Type
8.3.2.5.3. Spain Cancer Vaccines Market, by Indication
8.3.2.5.4. Spain Cancer Vaccines Market, by End-user
8.3.2.6. Rest of Europe
8.3.2.6.1. Rest of Europe Cancer Vaccines Market, by Technology
8.3.2.6.2. Rest of Europe Cancer Vaccines Market, by Type
8.3.2.6.3. Rest of Europe Cancer Vaccines Market, by Indication
8.3.2.6.4. Rest of Europe Cancer Vaccines Market, by End-user
8.3.3. Europe Cancer Vaccines Market, by Technology
8.3.4. Europe Cancer Vaccines Market, by Type
8.3.5. Europe Cancer Vaccines Market, by Indication
8.3.6. Europe Cancer Vaccines Market, by End-user
8.4. Asia-Pacific
8.4.1. Key Market Trends and Opportunities
8.4.2. Asia-Pacific Cancer Vaccines Market, by Country
8.4.2.1. Japan
8.4.2.1.1. Japan Cancer Vaccines Market, by Technology
8.4.2.1.2. Japan Cancer Vaccines Market, by Type
8.4.2.1.3. Japan Cancer Vaccines Market, by Indication
8.4.2.1.4. Japan Cancer Vaccines Market, by End-user
8.4.2.2. China
8.4.2.2.1. China Cancer Vaccines Market, by Technology
8.4.2.2.2. China Cancer Vaccines Market, by Type
8.4.2.2.3. China Cancer Vaccines Market, by Indication
8.4.2.2.4. China Cancer Vaccines Market, by End-user
8.4.2.3. Australia
8.4.2.3.1. Australia Cancer Vaccines Market, by Technology
8.4.2.3.2. Australia Cancer Vaccines Market, by Type
8.4.2.3.3. Australia Cancer Vaccines Market, by Indication
8.4.2.3.4. Australia Cancer Vaccines Market, by End-user
8.4.2.4. India
8.4.2.4.1. India Cancer Vaccines Market, by Technology
8.4.2.4.2. India Cancer Vaccines Market, by Type
8.4.2.4.3. India Cancer Vaccines Market, by Indication
8.4.2.4.4. India Cancer Vaccines Market, by End-user
8.4.2.5. South Korea
8.4.2.5.1. South Korea Cancer Vaccines Market, by Technology
8.4.2.5.2. South Korea Cancer Vaccines Market, by Type
8.4.2.5.3. South Korea Cancer Vaccines Market, by Indication
8.4.2.5.4. South Korea Cancer Vaccines Market, by End-user
8.4.2.6. Rest of Asia-Pacific
8.4.2.6.1. Rest of Asia-Pacific Cancer Vaccines Market, by Technology
8.4.2.6.2. Rest of Asia-Pacific Cancer Vaccines Market, by Type
8.4.2.6.3. Rest of Asia-Pacific Cancer Vaccines Market, by Indication
8.4.2.6.4. Rest of Asia-Pacific Cancer Vaccines Market, by End-user
8.4.3. Asia-Pacific Cancer Vaccines Market, by Technology
8.4.4. Asia-Pacific Cancer Vaccines Market, by Type
8.4.5. Asia-Pacific Cancer Vaccines Market, by Indication
8.4.6. Asia-Pacific Cancer Vaccines Market, by End-user
8.5. LAMEA
8.5.1. Key Market Trends, Growth Factors, and Opportunities
8.5.2. LAMEA Cancer Vaccines Market, by Country
8.5.2.1. Brazil
8.5.2.1.1. Brazil Cancer Vaccines Market, by Technology
8.5.2.1.2. Brazil Cancer Vaccines Market, by Type
8.5.2.1.3. Brazil Cancer Vaccines Market, by Indication
8.5.2.1.4. Brazil Cancer Vaccines Market, by End-user
8.5.2.2. Argentina
8.5.2.2.1. Argentina Cancer Vaccines Market, by Technology
8.5.2.2.2. Argentina Cancer Vaccines Market, by Type
8.5.2.2.3. Argentina Cancer Vaccines Market, by Indication
8.5.2.2.4. Argentina Cancer Vaccines Market, by End-user
8.5.2.3. Turkey
8.5.2.3.1. Turkey Cancer Vaccines Market, by Technology
8.5.2.3.2. Turkey Cancer Vaccines Market, by Type
8.5.2.3.3. Turkey Cancer Vaccines Market, by Indication
8.5.2.3.4. Turkey Cancer Vaccines Market, by End-user
8.5.2.4. South Africa
8.5.2.4.1. South Africa Cancer Vaccines Market, by Technology
8.5.2.4.2. South Africa Cancer Vaccines Market, by Type
8.5.2.4.3. South Africa Cancer Vaccines Market, by Indication
8.5.2.4.4. South Africa Cancer Vaccines Market, by End-user
8.5.2.5. Rest of LAMEA
8.5.2.5.1. Rest of LAMEA Cancer Vaccines Market, by Technology
8.5.2.5.2. Rest of LAMEA Cancer Vaccines Market, by Type
8.5.2.5.3. Rest of LAMEA Cancer Vaccines Market, by Indication
8.5.2.5.4. Rest of LAMEA Cancer Vaccines Market, by End-user
8.5.3. LAMEA Cancer Vaccines Market, by Technology
8.5.4. LAMEA Cancer Vaccines Market, by Type
8.5.5. LAMEA Cancer Vaccines Market, by Indication
8.5.6. LAMEA Cancer Vaccines Market, by End-user

Chapter 9: Company Profiles
9.1. Advaxis Inc.
9.1.1. Company Overview
9.1.2. Company Snapshot
9.1.3. Operating Business Segments
9.1.4. Product Portfolio
9.1.5. Business Performance
9.1.6. Key Strategic Moves and Developments
9.2. Amgen Inc.
9.2.1. Company Overview
9.2.2. Company Snapshot
9.2.3. Operating Business Segments
9.2.4. Product Portfolio
9.2.5. Business Performance
9.3. Dynavax Technologies Corporation
9.3.1. Company Overview
9.3.2. Company Snapshot
9.3.3. Operating Business Segments
9.3.4. Product Portfolio
9.3.5. Business Performance
9.4. Generex Biotechnology Corporation
9.4.1. Company Overview
9.4.2. Company Snapshot
9.4.3. Operating Business Segments
9.4.4. Product Portfolio
9.4.5. Business Performance
9.5. GlaxoSmithKline plc (Gsk)
9.5.1. Company Overview
9.5.2. Company Snapshot
9.5.3. Operating Business Segments
9.5.4. Product Portfolio
9.5.5. Business Performance
9.5.6. Key Strategic Moves and Developments
9.6. Immunocellular Therapeutics, Ltd
9.6.1. Company Overview
9.6.2. Company Snapshot
9.6.3. Operating Business Segments
9.6.4. Product Portfolio
9.7. Merck & Co. Inc.
9.7.1. Company Overview
9.7.2. Company Snapshot
9.7.3. Operating Business Segments
9.7.4. Product Portfolio
9.7.5. Business Performance
9.7.6. Key Strategic Moves and Developments
9.8. Sanpower Group Co. Ltd. (Dendereon Corporation)
9.8.1. Company Overview
9.8.2. Company Snapshot
9.8.3. Operating Business Segments
9.8.4. Product Portfolio
9.8.5. Key Strategic Moves and Developments
9.9. Ubivac
9.9.1. Company Overview
9.9.2. Company Snapshot
9.9.3. Operating Business Segments
9.9.4. Product Portfolio
9.9.5. Key Strategic Moves and Developments
9.10. Vaccinogen, Inc.
9.10.1. Company Overview
9.10.2. Company Snapshot
9.10.3. Operating Business Segments
9.10.4. Product Portfolio
Note: Product cover images may vary from those shown
3 of 3

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll